Metabolite of nicotinamide; Specific and potent inhibitor of NNMT, increasing histone methylation at H3K4 and methylated H3K4 occupancy at gene promoters

Antipsychotic and sedative agent as a potent antagonist of H1, 5-HT2A, and alpha1-adrenergic receptors

Specific inhibitor of the histone H3 lysine 9 demethylase KDM4 in HeLa cells.

Copper ion chelator, causing the triple response phenotype by affecting copper ion transport in ethylene signaling from ATX1 to RAN1

Novel anti-secretory and antiulcer agent for treatment of peptic ulcer disease and hypersecretory disorders

First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitor that Overcome Clinically Acquired Resistance

Novel opioid ligand for treatment of overactive bladder, acting as a μ-opioid receptor partial agonist

Novel potent and selective inhibitor of Tropomyosin-related kinase A (TrkA)

First-in-class highly potent and selective inhibitor of TrmD (bacterial t-RNA-(N1G37) methyltransferase)

Potent and selective 5-HT3 receptor antagonist

Serotonin 5-HT3 receptor antagonist

Fluroquinolone antibiotic, suppressing c-Myc transcription and myeloma growth, inhibiting pannexin-1 channels through which ATP is released as find-me signals in apoptotic Jurkat cells

Novel Photosensitive and Photoswitchable TRPA1 Agonist, Optically Control Pain through Channel Desensitization

Novel potent and selective TRPA1 inhibitor, interacting with the N-terminal ankyrin repeat (ankyrinR) domain

Novel potent and selective TRPA1 inhibitor, interacting with the N-terminal ankyrin repeat (ankyrinR) domain

Novel potent and selective TRPA1 inhibitor, interacting with the N-terminal ankyrin repeat (ankyrinR) domain

Novel selective inhibitor of the transient receptor potential melastatin 2 (TRPM2) channel, exhibiting TRPM2 selectivity over TRPM8 and TRPV1 channels as well as phospholipase A2 and showing neuroprotective activity in vitro, and significantly reducing ce

Novel agonist of the transient receptor potential melastatin 8 (TRPM8) ion channel

Novel selective TRPV6 inhibitor

Novel TrxR1 inhibitor, selectively killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation

Natural DNA gyrase inhibitor, blocking leukotriene production, inhibiting P-glycoprotein, and showing anti-inflammatory and anti cancer activities

Natural Polycyclic Peptide from a Fungus-Derived Streptomycete

Novel highly selective negative allosteric modulator (NAM) of thyrotropin receptor (TSHR), binding at the ectodomain/TMD interface, between the converging helix, ECL1 and the IA, noncompetitively inhibiting PAM-C2-activation

Novel human thymic stromal lymphopoietin (TSLP) inhibitor

Novel isoform-selective inhibitor of the tumor-associated hCA IX and XII

Novel αvβ3 ligand, disrupting the integrin-MMP2 interaction and showing antiangiogenic activit, inhibiting angiogenesis and tumor growth in vivo

Novel antagonist of T-type calcium channels

First-in-class potent threonine tyrosine kinase (TTK) PROTAC, demonstrating strong TTK degradation in COLO-205 human colorectal cancer cells with DC 50 values of 1.7 nM

First-in-class potent threonine tyrosine kinase (TTK) PROTAC, demonstrating strong TTK degradation in COLO-205 human colorectal cancer cells with DC 50 values of 3.1 nM

Novel transthyretin (TTR) stabilizer, binding to the T4 binding pocket of TTR and preventing the dissociation of TTR to monomer

FLT3 Kinase Inhibitor, Overcoming Both Activating and Drug Resistance Mutations in FLT3 in Acute Myeloid Leukemia

LpxC substrate-analog inhibitor

Novel inhibitor of tubulin polymerization and caused HepG2 cells arrest in G2/M phase

Novel potent tubulin polymerization inhibitor, forming stable interactions in the colchicine-binding site of tubulin, showing significant antiproliferative activities on a panel of tumor cell lines

Novel allosteric modulator of free fatty acid receptor 3 (FFA3, previously GPR41)

Novel allosteric modulator of free fatty acid receptor 3 (FFA3, previously GPR41)

Long-acting beta2-adrenergic receptor agonist

Novel Inhibitor of Metastatic Cancer Cell Migration and Invasion

Antibiotic, inhibiting the first step in the N-linked glycosylation in eukaryotes and inducing ER stress to activate the unfolded protein response (UPR)

Inhibitor of bacterial biofilm formation in Staphylococcus epidermidis

Natural potent porcine pancreatic elastase (PPE) inhibitor

Novel anticancer agent, affecting steroid biosynthesis, increasing RagD expression, and causing abnormal cellular cholesterol localization

Novel disruptor of the bacterial protein, FtsZ

Chymase inhibitor, preventing the development and progression of non-alcoholic steatohepatitis, improving vascular dysfunction and survival in stroke-prone spontaneously hypertensive rats

Novel highly potent and selective TYK2 JH2 inhibitor, providing robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model

First-in-class selective PRMT5 inhibitor, blocking EBV-driven B lymphocyte transformation and survival while leaving normal B cells unaffected

Stable analog of phosphotyrosine (pTyr)

Novel competitive inhibitor of tyrosinase enzyme

Potent and selective dopamine D4 receptor antagonist

Novel potent inhibitor of microtubule polymerization, binding directly to tubulin α/β heterodimers via the colchicine-binding site, perturbing mitotic spindles, delaying cells in mitosis and promotes apoptosis

Novel potent and broad-spectrum antiviral agent against multiple strains of EV-D68, EV-A71, and CVB3, targeting the viral protein 2C

Selective modulator of NMDA_receptor>NMDA receptors, potentiates responses at GluN1/GluN2A

Novel pan-inhibitor of GluN1/GluN2 receptors

Novel pan potentiator of GluN1/GluN2 receptors

Novel NMDAR positive allosteric modulator (PAM), robustly potentiating responses at all GluN1/GluN2 subtypes and at neuronal NMDARs

Novel Antagonist of the USP5 Zinc Finger Ubiquitin-Binding Domain (USP5 ZnF-UBD)

Modulator of cyclic AMP generation, amplifing induced cyclic AMP formation in rat brain tissue; Nootropic

Potent ligand of synaptic vesicle protein 2A (SV2A)

Novel inhibitor of TNF signalling by stabilising an asymmetric form of the trimer, displaying a concentration-dependent response curve and selectivity over the TNFR1 extracellular domain and control proteins

Novel inhibitor of TNF signalling by stabilising an asymmetric form of the trimer, displaying a concentration-dependent response curve and selectivity over the TNFR1 extracellular domain and control proteins

Novel allosteric modulator of neonatal Fc receptor (FcRn), binding to the extracellular domain of FcRn

Selective competitive inhibitor of ATX-mediated hydrolysis of the lysophospholipase substrate FS-3

Selective competitive inhibitor of ATX-mediated hydrolysis of the lysophospholipase substrate FS-3

Competitive dual inhibitor of the hydrolysis FS-3 and the phosphodiesterase substrate p-nitrophenyl thymidine 5'-monophosphate

Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors

Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors

Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors

Histamine H3 Receptor Antagonist in Treatments of Cognition Disorders

The first potent nonimidazole H3 receptor antagonist (pKi=8.40)

Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), Showing Efficacy in Neuropathic Pain Amelioration

Novel potent isoprenylcysteine carboxylmethyltransferase (ICMT) inhibitor, improving survival in Ras-driven acute myeloid leukemia

Dual inhibitor of fatty acid amide hydrolase (FAAH) and α/β hydrolase domain 6 (ABHD6)

Stereoisomer of UCN-01, inhibiting protein kinase C with a slightly reduced potency than UCN-01

Novel dual inhibitor of dihydrofolate reductase (DHFR) and its functional analog, Rv2671

Fluorescent excitatory amino acid transporter subtype 1 (EAAT1) selective inhibitor

Potent and selective 11ß-HSD1 inhibitor, improving memory, including after intracerebroventricular drug administration to the central nervous system alone

Novel selective delta-opioid receptor agonist

Novel Nicotinic Acetylcholine Receptor Antagonist, Inhibiting Nicotine Reward and Decreases Anxiety and Decreasing Ethanol Intake in Alcohol-Preferring Rats

Novel inhibitor of UGM, impeding C. glutamicum growth

Novel inhibitor of UGM, impeding C. glutamicum growth

Novel potent human immunodeficiency virus type 1 (HIV-1) protease inhibito

Selective NEP inhibitor for treatment of the symptoms of Female sexual arousal disorder (FSAD)

Selective NEP inhibitor for treatment of the symptoms of Female sexual arousal disorder (FSAD)

Potent VMAT2 inhibitor

Novel chemically stable fluorescent marker of the ureter

Novel Vaccine Adjuvant for Mycobacterium tuberculosis

Novel potent and selective dual PLK1 and BRD4 inhibitor, inducing apoptosis in pediatric tumor cell lines, leading to significant tumor regression

Novel, Potent, and Selective CBP/P300 Inhibitor

Novel Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitor

Novel anti-virulence agent, rescuing nematodes from a Staphylococcus aureus infection and preventing the formation of biofilm in a dose-dependent manner without interfering with bacterial viability

Novel fluorescent UnaG ligand, binding UnaG with high affinity (Kd = 3 nM) to induce a 2.5-fold fluorescence intensity enhancement and a 10 nm red shift

Novel nonhematotoxic DNA intercalating agent with potent antitumor activity, inducing apoptosis via inhibition of key proteins in the PI3K/Akt/mTOR signaling pathway

UNC0737 is a negative control of UNC0638 and the N-methyl analog of UNC0638. UNC0737 was designed to eliminate the hydrogen bond interaction seen in the G9a-UNC0224 cocrystal structure between Asp1083 of G9a and the secondary amino group at the 4-position of UNC0224's quinazoline ring3. UNC0737 was >300-fold less potent than UNC0638 in G9a and GLP biochemical assays. As expected, UNC0737 was a poor inhibitor of G9a (IC50 = 5,000 ± 200 nM (n = 2)) and GLP (IC50 > 10,000 nM (n = 2)) in the SAHH-coupled assays.

Biotinylated UNC0638, enabling chemiprecipitation of G9a from whole cell lysates

Novel MYC protein stablizer, increasing the abundance of endogenous MYC proteintargeting the receptor tyrosine kinases KIT and platelet-derived growth factor receptor α (PDGFRα)

Novel inhibitor of ROP18, inhibiting ROP18 within cells, and abrogating its effects on the host IRG pathway

Novel Peptide Inhibitor for Calcium and Integrin Binding Protein 1 (CIB1)

Negative control for UNC1666 which is a dual Mer and Flt-3 tyrosine kinase inhibitor

Orally Active Adenosine A 1 Receptor Agonist

Novel Ligand of EEDm acting as an allosteric inhibitor of PRC2

Novel allosteric inhibitor of PRC2 catalytic activity

Novel allosteric inhibitor of PRC2 catalytic activity

Novel selective activator of PRC2-EED-I363M, showing minimal effects on the activity of PRC2-WT

Novel selective activator of PRC2-EED-I363M, showing minimal effects on the activity of PRC2-WT

Novel inhibitor for histone methyllysine reader proteins (KmeRP), targeting CBX5 chromodomain

Novel inhibitor for histone methyllysine reader proteins (KmeRP), targeting CBX5 chromodomain

Novel peptidomimetic antagonist of the PHF1 Tudor domain, binding both PHF1 Tudor domain and the related protein PHF19

Novel inhibitor for histone methyllysine reader proteins (KmeRP), targeting CBX5 chromodomain

Novel potent and selective PAM of CBX8, blocking H3K27me3 binding and enhancing CBX8 affinity for nucleic acids, evicting PRC1 from H3K27me3 targets triggering DLBCL cell differentiation

Novel β-arrestin-biased D2 receptor (D2R) agonist

Novel Eph antagonist, inhibiting Eph/ephrin interactions, enhancing glucose-stimulated insulin secretion (GSIS), and acting as a hypoglycemic agent

The first bifunctional (chemoreactive and clickable) probe for Adenosine A1 and A3 Receptors

Potent kynurenine 3-monooxygenase (kynurenine 3-hydroxylase; KMO) inhibitor

Novel superagonist of the urotensin-II (UT) receptor

Novel Potent antagonist of the Urotensin-II (UT) Receptor

Novel superagonist of the urotensin-II (UT) receptor

Novel potent antagonist of the Urotensin-II (UT) receptor

Novel E-Selectin antagonist, disrupting cell survival pathway activation, enhancing chemotherapy response and protecting from toxicity such as mucositis with improved survival in vivo

Novel Neuropeptide Y Y4 Receptor (Y4R) Antagonist (pK i values <7.57)

Novel Potent Neuropeptide Y Y4 Receptor (Y4R) Partial Agonist (pK i : 8.47)

Natural flavonoid from the leaves of Glycyrrhiza uralensis

Novel Red-Emitting Fluorescent Dualsteric Probe for the Muscarinic Acetylcholine M2 Receptor

Novel FAAH inhibitor

Potent, selective, and irreversible inhibitor of fatty acid amide hydrolase (FAAH)

Novel potent partial agonist of histamine H4 receptors (H4R)

Novel potent partial agonist of histamine H4 receptors (H4R)

Py-5-Labeled Fluorescent Multipurpose Probe for Investigations on the Histamine H3 and H4 Receptors, acting as a partial agonist at the hH3R [pEC50 (reporter gene) 8.77] and as an inverse agonist/antagonist at the h/mH4Rs [pIC50 (reporter gene) 8.76/7.08;

Novel subtype selective histamine H2 receptor G protein-biased agonist

Novel H2 receptor agonist, functionally stimulating human cardiac H2 receptors in vitro and in vivo

Novel H2 receptor agonist, functionally stimulating human cardiac H2 receptors in vitro and in vivo

Novel NPY Y1 Receptor Antagonist

Novel fluorescent histamine H3 receptor ligand

Novel H2 receptor agonist, functionally stimulating human cardiac H2 receptors in vitro and in vivo

Novel USP30 inhibitor, increasing Ub-TOM20 with an EC50 of 2.45 mM and inducing the maximal Ub-TOM20

Novel kidney urea transporter UT-A1 inhibitor

Novel

Quorum sensing modulator as a LasR antagonist

Non-immunosuppressive immunophilins ligand, demonstrating enhanced neuroregeneration in the peripheral nervous system and CNS

Novel Long Residence Time Superior Inhibitor of the Vasopressin V2 Receptor

Novel Mycobacterium Tuberculosis VapC-Activating Stapled Peptide, successfully penetrated Mycobacterium smegmatis cell membranes and exerted bactericidal activity at a minimum inhibitory concentration that inhibited 50% of the isolates (MIC50) < 6.25 μM

Novel potent inhibitor of FGFR4 kinase activity

Specific inhibitor of tissue Kallikrein>kallikrein

Selective 5-HT2C receptor full agonist

Orally acting antinociceptive muscarinic agonist

Prodrug of ganciclovir for treatment of cytomegalovirus (CMV) infection in those with HIV/AIDS or following organ transplant

Natural pseudo-aminosugar

Novel prodrug of luciferin to mimic the transport and activation of valacyclovir, , being a robust and functional determinant of VACVase activity

Novel selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability

Novel osteoclastogenesis inhibitor, preventing ovariectomy-induced osteoporosis in ddY mice

Partial α4ß2 nicotinic receptor agonist and α7 full agonist

Natural inhibitor of β-hexosaminidase release and tumor necrosis factor (TNF)-α secretion from rat basophilic leukemia (RBL 2H3) cells, with IC50 values of 10.4 μM and 16.8 μM, respectively, also inhibiting PKC β1 activity with an IC50 value of 36.2 μM

Novel anticryptosporidial agent, acting as a toll-like receptor-2 (TLR2) antagonist

Novel potent TLR‐4 activation inhibitor, attenuating the expression of fibrosis hallmark genes collagen, fibronectin (FN) and transforming growth factor β (TGF‐β) in kidneys and improved albumin/creatinine ratio with higher efficacy

Novel potent inhibitor of VDAC1, directly interacting with purified VDAC1 and reducing its channel conductance

Novel inhibitor of VDAC1 oligomerization and apoptosis

Novel non-nucleoside inhibitor of HCV RNA-dependent polymerase

Novel selective inhibitor of the γ-class enzyme of bacteria Vibrio cholerae A (VchCAγ)

Novel potent and selective CA IX inhibitor

Novel potent and selective CA IX inhibitor

Novel nonsecosteroidal vitamin D receptor (VDR) modulator, enhancing pancreatic cancer therapy through remodeling of the tumor microenvironment by combination with gemcitabine

Novel nonsecosteroidal vitamin D receptor (VDR) modulator, enhancing pancreatic cancer therapy through remodeling of the tumor microenvironment by combination with gemcitabine

Novel nonsecosteroidal vitamin D receptor (VDR) modulator, enhancing pancreatic cancer therapy through remodeling of the tumor microenvironment by combination with gemcitabine

Novel Aurora kinase inhibitor

Potent, Vascular Endothelial Growth Factor Receptor-​2 (VEGFR-2) Tyrosine Kinase Inhibitor

Activator for Proprietary Gene Therapy Promoter System

Serotonin-norepinephrine reuptake inhibitor (SNRI); Antidepressant

Novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupting Warburg metabolism and inducing context-dependent cytostasis in cancer cells

Antitumor agent

Natural Janus-Faced Modulator of Voltage-Gated Sodium Ion Channels, acting on the channel as either an agonist or antagonist depending on the nature of the electrophysiological stimulation protocol

Natural anti-inflammatory and antioxidant agent, inhibiting both iNOS expression and NO release in the LPS-induced J774.A1 macrophage cell line, enhancing protein expression levels of PARP-1 and p53, and attenuating intracellular ROS and stress (oxidative

Novel blocker of atrial potassium channels

Natural Reversible Plant Growth Inhibitor

Natural insect ryanodine receptor (RyR) antagonist

Apoptosis inducer, inhibiting Leiomyosarcoma and Malignant peripheral nerve sheath tumor growth

Potent inhibitor of acetylcholine transport

Novel anti-vesiculoviral agent, inhibiting transcription initiation of vesiculoviruses

Novel Inhibitor of the Pro-Angiogenic Activity of the Zinc Finger Transcription Factor Vezf1

The first sub-micromolar inhibitor of the VHL-HIF1α interaction

Natural protein kinase C (PKC) activator and HSP90 inhibitor, sensitizing human acute myeloid leukemia cells to tyrosine kinase inhibitor-induced myeloid differentiation via activation of PKC and upregulation of Lyn

Clopidogrel analog as an antiplatelet agent

Broad spectrum antibiotic, inhibiting adenylyl cyclase type 5 (AC5) and protecting against chronic coronary artery occlusion (CAO)

Selective long-acting beta2-adrenergic agonist (LABA) with inherent 24-hour activity for once daily treatment of COPD and asthma

Novel antagonist against hypocretin (orexin) receptor 2, significantly preventing acute morphine-conditioned place preference (CPP) and stress-induced reinstatement of extinguished morphine-CPP in mouse models of opioid reward and relapse

Natural inhibitor of 3C-like protease (3CLpro), targeting SARS-CoV-2 3CLpro, SARS-CoV 3CLpro and MERS-CoV 3CLpro

Natural antimicrobial, antioxidant, and anti-inflammator agent

Endogenous cannabinoid receptor mixed agonist/antagonist, being a full agonist at GPR55 and CB2 and partial agonist/antagonist at CB1

Natural inhibitor of ST2 (IL1RL1)

Coelenterazine analog for bioluminescence imaging (BLI)

Fluorescent cyclin-dependent kinase inhibitor, blocking the proliferation of human breast cancer cells

Novel and selective desensitizer of

Novel highly-selective melanocortin-4 receptor (MC4R) agonist, increasing resting energy expenditure in obese individuals

Novel potent VEGFR2 modulator, exhibiting increased antiangiogenic potency than voacangine against VEGF-induced VEGFR2 phosphorylation without cytotoxic effects, resulting in significant tumor cell death in a mouse xenograft model

Novel calcineurin inhibitor and immunosuppressive agent

Novel potassium-competitive acid blocker

Novel potent and highly selective type-II inhibitor of p38α/β, targeting an inactive state of the kinases induced by a unique folded P-loop conformation

Potent Antiandrogen, Targeting the BF3 Site of the Androgen Receptor and Inhibiting Enzalutamide-Resistant Prostate Cancer

Novel potent and selective inhibitor of ERα-dependent cell growth and gene expression, preventing the interaction between ERα-LBD and SRC-3 fusion proteins in a dose-dependent manner

S1P1/S1P3 receptor agonist

Novel Androgen Receptor Antagonist, inhibiting the LNCaP cell line as well as cell lines with wild-type androgen receptor

Competitive S1P1/3 antagonist, increasing capillary permeability as measured by Evans blue dye leakage in mouse lung tissue